Bildkälla: Stockfoto

Arocell: Planned stock-for-stock merger with IDL Biotech - Redeye

Redeye comments AroCell’s bid on diagnostics company IDL Biotech. The decision to venture into M&A activities came as a surprise to us and requires further digging before providing a more in-depth take on the news and its impact on the now altered case. Still, we summarize the announcement following a meeting with management.

Redeye comments AroCell’s bid on diagnostics company IDL Biotech. The decision to venture into M&A activities came as a surprise to us and requires further digging before providing a more in-depth take on the news and its impact on the now altered case. Still, we summarize the announcement following a meeting with management.
Börsvärldens nyhetsbrev
ANNONSER